PURPOSE: Despite multiple randomized trials showing the efficacy of hypofractionated radiation therapy in early-stage breast cancer, the United States has been slow to adopt this treatment. The goal of this study was to evaluate the impact of individual radiation oncologists on the early adoption of hypofractionated radiation therapy for early-stage breast cancer. METHODS: We identified 22,233 Medicare beneficiaries with localized breast cancer that was diagnosed from 2004 to 2011 who underwent breast-conserving surgery with adjuvant radiation. Multilevel, multivariable logistic models clustered by radiation oncologist and geographic practice area were used to determine the impact of the provider and geographic region on the likelihood of receiving hypofractionated compared with standard fractionated radiation therapy while controlling for a patient's clinical and demographic covariates. Odds ratios (OR) describe the impact of demographic or clinical covariates, and the median OR (MOR) describes the relative impact of the individual radiation oncologist and geographic region on the likelihood of undergoing hypofractionated radiation therapy. RESULTS: Among the entire cohort, 2333 women (10.4%) were treated with hypofractionated radiation therapy, with unadjusted rates ranging from 0.0% in the bottom quintile of radiation oncologists to 30.4% in the top quintile. Multivariable analysis found that the individual radiation oncologist (MOR 3.08) had a greater impact on the use of hypofractionation than did geographic region (MOR 2.10) or clinical and demographic variables. The impact of the provider increased from the year 2004 to 2005 (MOR 2.82) to the year 2010 to 2011 (MOR 3.16) despite the publication of long-term randomized trial results in early 2010. Male physician and radiation oncologists treating the highest volume of breast cancer patients were less likely to perform hypofractionation (P<.05). CONCLUSIONS: The individual radiation oncologist strongly influenced the likelihood of a patient's receiving hypofractionated radiation therapy, and this trend increased despite the publication of long-term data showing equivalence to standard fractionation. Future research should focus on physician-related factors that influence this decision.
PURPOSE: Despite multiple randomized trials showing the efficacy of hypofractionated radiation therapy in early-stage breast cancer, the United States has been slow to adopt this treatment. The goal of this study was to evaluate the impact of individual radiation oncologists on the early adoption of hypofractionated radiation therapy for early-stage breast cancer. METHODS: We identified 22,233 Medicare beneficiaries with localized breast cancer that was diagnosed from 2004 to 2011 who underwent breast-conserving surgery with adjuvant radiation. Multilevel, multivariable logistic models clustered by radiation oncologist and geographic practice area were used to determine the impact of the provider and geographic region on the likelihood of receiving hypofractionated compared with standard fractionated radiation therapy while controlling for a patient's clinical and demographic covariates. Odds ratios (OR) describe the impact of demographic or clinical covariates, and the median OR (MOR) describes the relative impact of the individual radiation oncologist and geographic region on the likelihood of undergoing hypofractionated radiation therapy. RESULTS: Among the entire cohort, 2333 women (10.4%) were treated with hypofractionated radiation therapy, with unadjusted rates ranging from 0.0% in the bottom quintile of radiation oncologists to 30.4% in the top quintile. Multivariable analysis found that the individual radiation oncologist (MOR 3.08) had a greater impact on the use of hypofractionation than did geographic region (MOR 2.10) or clinical and demographic variables. The impact of the provider increased from the year 2004 to 2005 (MOR 2.82) to the year 2010 to 2011 (MOR 3.16) despite the publication of long-term randomized trial results in early 2010. Male physician and radiation oncologists treating the highest volume of breast cancerpatients were less likely to perform hypofractionation (P<.05). CONCLUSIONS: The individual radiation oncologist strongly influenced the likelihood of a patient's receiving hypofractionated radiation therapy, and this trend increased despite the publication of long-term data showing equivalence to standard fractionation. Future research should focus on physician-related factors that influence this decision.
Authors: Joan L Warren; Michael J Barrett; Dolly P White; Robert Banks; Susannah Cafardi; Lindsey Enewold Journal: J Natl Cancer Inst Monogr Date: 2020-05-01
Authors: Andrea M Austin; Nirav S Kapadia; Gabriel A Brooks; Tracy L Onega; A Heather Eliassen; Rulla M Tamimi; Michelle Holmes; Qianfei Wang; Francine Grodstein; Anna N A Tosteson Journal: Breast Cancer Res Treat Date: 2019-01-03 Impact factor: 4.872
Authors: Katherine E Mues; Alexander Liede; Jiannong Liu; James B Wetmore; Rebecca Zaha; Brian D Bradbury; Allan J Collins; David T Gilbertson Journal: Clin Epidemiol Date: 2017-05-09 Impact factor: 4.790
Authors: Kelsey L Corrigan; Xiudong Lei; Neelofur Ahmad; Isidora Arzu; Elizabeth Bloom; Stephen G Chun; Chelain Goodman; Karen E Hoffman; Melissa Joyner; Lauren Mayo; Melissa Mitchell; Kevin T Nead; George H Perkins; Valerie Reed; Jay P Reddy; Pamela Schlembach; Simona F Shaitelman; Michael C Stauder; Eric A Strom; Welela Tereffe; Lee Wiederhold; Wendy A Woodward; Benjamin D Smith Journal: Adv Radiat Oncol Date: 2021-12-24
Authors: Leticia M Nogueira; Helmneh M Sineshaw; Ahmedin Jemal; Craig E Pollack; Jason A Efstathiou; K Robin Yabroff Journal: JAMA Netw Open Date: 2022-04-01
Authors: Xiao Xu; Pamela R Soulos; Jeph Herrin; Shi-Yi Wang; Craig Evan Pollack; Suzanne B Evans; James B Yu; Cary P Gross Journal: Health Serv Res Date: 2020-10-18 Impact factor: 3.734
Authors: Luca F Valle; Fang-I Chu; Palak Kundu; Stephanie M Yoon; Travis Gilchrist; Michael L Steinberg; Ann C Raldow Journal: Cancer Med Date: 2021-06-02 Impact factor: 4.452